Comparison of FDA Approved Kinase Targets to Clinical Trial Ones: Insights from Their System Profiles and Drug-Target Interaction Networks

Figure 3

Distribution of phase 1 (yellow), phase 2 (green), and phase 3 (orange) clinical trial targets by level of similarity to established targets. The level of similarity to established targets is classified into very similar, marginally similar, and unsimilar with the BLAST -values in the range of ≤0.001 and 0.001~0.1 and >0.1, respectively.